{
  "component_scores": {
    "joint_involvement": {
      "score": 5,
      "justification": "Polyarthrite rhumatoïde mentioned multiple times and confirmed in the patient facts."
    },
    "serology": {
      "score": 3,
      "justification": "Anti-CCP (ACPA) is negative, but RF is positive. This falls under the category of High-positive RF or high-positive ACPA (>3× ULN)."
    },
    "acute_phase": {
      "score": 0,
      "justification": "CRP and VHS values are unknown."
    },
    "duration": {
      "score": 1,
      "justification": "Patient is on adalimumab (bDMARD) which suggests chronic/long-standing disease, even if not explicitly stated."
    }
  },
  "acr_eular_total": 9,
  "treatment_context": {
    "has_dmard": true,
    "treatment_strength": "strong",
    "justification": "Patient is on adalimumab (bDMARD), providing strong evidence for established RA"
  },
  "final_label": "RA+",
  "classification_rationale": "The patient has a high score in the joint involvement category due to multiple mentions of polyarthrite rhumatoïde. The serology category is scored at 3 points for positive RF, which aligns with established guidelines. The treatment context provides strong evidence of established RA with adalimumab being a biologic DMARD (bDMARD). Therefore, the final classification is RA+.",
  "confidence": "high",
  "patient_id": "0011",
  "agent": "Agent2_LLM_Reasoning_BALANCED",
  "retrieved_guidelines": [
    {
      "title": "Clinical Context",
      "content": "Treatment patterns provide additional evidence:\n- Methotrexate (MTX) = first-line csDMARD\n- Biologic DMARDs (anti-TNF, anti-IL6, etc.) = established RA\n- JAK inhibitors = treatment-refractory RA\n\nIn clinical practice:\n- Score ≥6/10 = definite RA\n- Score 4-5/10 + DMARD treatment = probable established RA\n- Score ≥5/10 without treatment = borderline, likely RA",
      "text": "Clinical Context Treatment patterns provide additional evidence:\n- Methotrexate (MTX) = first-line csDMARD\n- Biologic DMARDs (anti-TNF, anti-IL6, etc.) = established RA\n- JAK inhibitors = treatment-refractory RA\n\nIn clinical practice:\n- Score ≥6/10 = definite RA\n- Score 4-5/10 + DMARD treatment = probable established RA\n- Score ≥5/10 without treatment = borderline, likely RA",
      "relevance_score": 4.683000883810066
    },
    {
      "title": "Category B: Serology (0-3 points)",
      "content": "- Negative RF AND negative ACPA: 0 points\n- Low-positive RF OR low-positive ACPA (≤3× ULN): 2 points\n- High-positive RF OR high-positive ACPA (>3× ULN): 3 points\n\nRF = Rheumatoid Factor\nACPA = Anti-citrullinated protein antibody (anti-CCP)\nULN = Upper limit of normal (typically RF: 20 IU/mL, anti-CCP: 10 U/mL)",
      "text": "Category B: Serology (0-3 points) - Negative RF AND negative ACPA: 0 points\n- Low-positive RF OR low-positive ACPA (≤3× ULN): 2 points\n- High-positive RF OR high-positive ACPA (>3× ULN): 3 points\n\nRF = Rheumatoid Factor\nACPA = Anti-citrullinated protein antibody (anti-CCP)\nULN = Upper limit of normal (typically RF: 20 IU/mL, anti-CCP: 10 U/mL)",
      "relevance_score": 3.7519987234196357
    },
    {
      "title": "Category A: Joint Involvement (0-5 points)",
      "content": "- 1 large joint: 0 points\n- 2-10 large joints: 1 point\n- 1-3 small joints (with or without large joints): 2 points\n- 4-10 small joints (with or without large joints): 3 points\n- >10 joints (at least 1 small joint): 5 points\n\nLarge joints: shoulders, elbows, hips, knees, ankles\nSmall joints: MCPs, PIPs, MTPs (2nd-5th), thumb IPs, wrists",
      "text": "Category A: Joint Involvement (0-5 points) - 1 large joint: 0 points\n- 2-10 large joints: 1 point\n- 1-3 small joints (with or without large joints): 2 points\n- 4-10 small joints (with or without large joints): 3 points\n- >10 joints (at least 1 small joint): 5 points\n\nLarge joints: shoulders, elbows, hips, knees, ankles\nSmall joints: MCPs, PIPs, MTPs (2nd-5th), thumb IPs, wrists",
      "relevance_score": 2.188326647736484
    }
  ],
  "guideline_citation": "Aletaha D, et al. Arthritis Rheum. 2010;62(9):2569-2581",
  "evidence_trace": [
    {
      "type": "disease_mention",
      "stay_id": "",
      "line_no": "005",
      "snippet": "Diagnostic évoqué : arthrose, pas de PR."
    },
    {
      "type": "disease_mention",
      "stay_id": "",
      "line_no": "005",
      "snippet": "Diagnostic évoqué : arthrose, pas de PR."
    },
    {
      "type": "disease_mention",
      "stay_id": "S0021",
      "line_no": 5,
      "snippet": "Diagnostic évoqué : arthrose, pas de PR."
    },
    {
      "type": "disease_mention",
      "stay_id": null,
      "line_no": "001",
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "disease_mention",
      "stay_id": null,
      "line_no": "007",
      "snippet": "Diagnostic : pyélonéphrite. Prise en charge : antibiotiques, arrêt temporaire de l’adalimumab."
    },
    {
      "type": "disease_mention",
      "stay_id": null,
      "line_no": "001",
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "disease_mention",
      "stay_id": "S0022",
      "line_no": 1,
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "lab",
      "test": "RF",
      "stay_id": "",
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 10 mg/L, VHS 20 mm/h, RF : négatif (8 UI/mL), anti-CCP : négatif (<5 U/mL)."
    },
    {
      "type": "lab",
      "test": "anti-CCP",
      "stay_id": "",
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 10 mg/L, VHS 20 mm/h, RF : négatif (8 UI/mL), anti-CCP : négatif (<5 U/mL)."
    },
    {
      "type": "lab",
      "test": "CRP",
      "stay_id": "",
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 10 mg/L, VHS 20 mm/h, RF : négatif (8 UI/mL), anti-CCP : négatif (<5 U/mL)."
    },
    {
      "type": "lab",
      "test": "VHS",
      "stay_id": "",
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 10 mg/L, VHS 20 mm/h, RF : négatif (8 UI/mL), anti-CCP : négatif (<5 U/mL)."
    },
    {
      "type": "lab",
      "test": "RF",
      "stay_id": null,
      "line_no": "001",
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "lab",
      "test": "anti-CCP/ACPA",
      "stay_id": null,
      "line_no": "001",
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "lab",
      "test": "CRP",
      "stay_id": null,
      "line_no": "001",
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "drug",
      "name": "adalimumab",
      "stay_id": null,
      "line_no": "001",
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "drug",
      "name": "ampicilline",
      "stay_id": null,
      "line_no": "005",
      "snippet": "Culture urinaire : E. coli sensible à l’ampicilline."
    },
    {
      "type": "drug",
      "name": "antibiotiques",
      "stay_id": null,
      "line_no": "007",
      "snippet": "Prise en charge : antibiotiques, arrêt temporaire de l’adalimumab."
    }
  ]
}